NEW YORK (GenomeWeb) – A team led by Johns Hopkins Kimmel Cancer Center researchers has developed a model that uses routine pathologic parameters to identify breast cancer patients for whom molecular-based recurrence testing with Oncotype DX is likely to provide added information.